During chemotherapy or targeted therapy, doctors need to know early whether the tumour is shrinking. AI compares imaging across time points — the same lesion, the same measurements — and detects subtle changes earlier than standard visual comparison.
The same principle applies after treatment: AI can flag suspicious changes that might signal recurrence, triggering earlier investigation. For the millions of women living with or after breast cancer, this continuous watch adds an extra layer of vigilance.
What AI monitors
- Tumour size and density across exams
- Response or resistance during neoadjuvant therapy
- Early signs of recurrence after treatment
- Side-effect patterns in real-world data